First reported late last year, Sense Biodetection has confirmed a $50m series B round backed by Cambridge Innovation Capital.
Sense Biodetection, a UK-based molecular diagnostics technology developer, has secured $50m in series B funding from investors including Cambridge Innovation Capital (CIC).
Koch Disruptive Technologies (KDT), a subsidiary of chemicals and industrial group Koch Industries, led the round, which was first rumoured in November 2020.
The round also featured Earlybird Health Tech Fund, a fund managed by venture capital firm Earlybird, as well as Mercia Asset Management and private investor Jonathan Milner.
Sense Biodetection is developing handheld molecular diagnostics…
